EUVIMEDEUVIMED entdecken
Crossref

Non-canonical PRC1.1 licenses transcriptional response to enable Treg plasticity in immune adaptation

Ting Li, Yingying Zhao, Qian Li, Zhaoran Sun, Ni Wang, Liangyu Xing, Nan Tang, Runyuan Mao, Yuxin Wang, Jiacheng Su, Dawei Huo, Feng Dong und 15 weitere

Molecular Cell · 2025

DOI: 10.1016/j.molcel.2025.05.029 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Cell, 2025. Verfasst von Ting Li und 26 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative I…. Hauptthemen laut MEDLINE: T-Lymphocytes, Regulatory, Jumonji Domain-Containing Histone Demethylases, F-Box Proteins, Polycomb Repressive Complex 1. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 92 Literaturangaben. Gefördert von: China Postdoctoral Science Foundation, National Key Research and Development Program of China, Tianjin Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Polycomb repressive complexes (PRCs) sustain regulatory T (Treg) cell identity through transcriptional silencing, yet their role in modulating Treg functional plasticity during immune adaptation remains unclear. Here, we identify KDM2B, a defining component of non-canonical PRC1.1, as a critical regulator for sustaining the proportion and immunosuppressive functions of active Treg (aTreg) cells without altering Treg abundance or identity. Mechanistically, PRC1.1 deposits H2AK119 monoubiquitylation (H2AK119ub1) at active promoters, enabling rather than repressing transcriptional activation of aTreg programs. Disruption of PRC1.1 via Kdm2b ablation or pharmacological inhibition with iBP, a selective inhibitor, reduces H2AK119ub1, blunts stimulus-dependent transcriptional activation, and suppresses Treg activation. Notably, Treg-specific Kdm2b deletion in melanoma-bearing mice enhances anti-tumor immunity and synergizes with anti-PD-L1 therapy. Therefore, our study underscores H2AK119ub1 as a dual-function epigenetic mark and PRC1.1 as a molecular rheostat fine-tuning Treg adaptability, establishing PRC1.1 as a therapeutic target to decouple immune suppression in cancer while preserving Treg homeostasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

T-Lymphocytes, RegulatoryJumonji Domain-Containing Histone DemethylasesF-Box ProteinsPolycomb Repressive Complex 1Cell PlasticityAnimalsMiceHumansMice, Inbred C57BLUbiquitinationHistonesMice, KnockoutMelanoma, Experimental

Stichwörter der Autor:innen

H2AK119ub1PRCPolycombTregplasticitytumor-infiltrated Treg

Substanzen

Jumonji Domain-Containing Histone DemethylasesF-Box ProteinsPolycomb Repressive Complex 1Histones

Autor:innen und Institutionen

  • State Key Laboratory of Experimental Hematology, National Clinical Research Center for Cancer, The Province and Ministry Co-sponsored Collaborative Innovation Center for Medical Epigenetics, Key Laboratory of Immune Mic…
  • Fudan University Shanghai Cancer Center, Institutes of Biomedical Sciences, State Key Laboratory of Genetic Engineering, Shanghai Key Laboratory of Medical Epigenetics, Shanghai Key Laboratory of Radiation Oncology, Hum…
  • Department of Pathology, Tianjin First Central Hospital, Tianjin, China.
  • Department of Neurosurgery, Medical Research Institute, Frontier Science Center of Immunology and Metabolism, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, China.
  • Department of Immunology and Microbiology, Shanghai Institute of Immunology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianji…

Förderung

  • China Postdoctoral Science Foundation
  • National Key Research and Development Program of China
  • Tianjin Medical University
  • National Natural Science Foundation of China

Zitieren

APA

Li, T., Zhao, Y., Li, Q., Sun, Z., Wang, N., Xing, L., Tang, N., Mao, R., Wang, Y., Su, J., Huo, D., Dong, F., Zhao, X., Cao, L., Kong, Y., Gong, M., Liu, Z., Li, W., Lv, X., …, & Wu, X. (2025). Non-canonical PRC1.1 licenses transcriptional response to enable Treg plasticity in immune adaptation. Molecular Cell. https://doi.org/10.1016/j.molcel.2025.05.029

Vancouver

Li T, Zhao Y, Li Q, Sun Z, Wang N, Xing L, et al. Non-canonical PRC1.1 licenses transcriptional response to enable Treg plasticity in immune adaptation. Molecular Cell. 2025. doi:10.1016/j.molcel.2025.05.029

BibTeX
@article{Li2025,
  author = {Li, Ting and Zhao, Yingying and Li, Qian and Sun, Zhaoran and Wang, Ni and Xing, Liangyu and Tang, Nan and Mao, Runyuan and Wang, Yuxin and Su, Jiacheng and Huo, Dawei and Dong, Feng and Zhao, Xiujuan and Cao, Lei and Kong, Yu and Gong, Meihan and Liu, Ziyi and Li, Wei and Lv, Xuejiao and Ning, Hanhan and Hu, Deqing and Zhou, Yan and Li, Bin and Feng, Xiaoming and Helin, Kristian and Chen, Fei Xavier and Wu, Xudong},
  title = {Non-canonical PRC1.1 licenses transcriptional response to enable Treg plasticity in immune adaptation},
  journal = {Molecular Cell},
  year = {2025},
  doi = {10.1016/j.molcel.2025.05.029}
}
Kostenlos starten →